European Psychiatry
June 1, 2022
Kaushal Shah, C. Trivedi, D. Kamrai et al.
6 citations
Introduction Psilocybin is a psychedelic drug found in mushrooms, often referred to as magic mushrooms due to its visual and auditory hallucinations effects upon ingestion. It is a Schedule I drug per DEA, and the FDA has not approved psilocybin for medicinal purposes. However, recent studies have shown promising therapeutic use to treat depression. Objectives To identify current use,...
Journal of Clinical Oncology
June 1, 2022
Manish Agrawal, Paul Thambi, Sarah Shnayder
3 citations
12097 Background: More than 17 million people in the U.S. live with cancer and up to 25% of them have major depression. Depression leads to lower treatment adherence, reduced quality of life, and higher rates of mortality in cancer. Yet, interventions used to treat depression in patients with cancer have limited success. Prior trials using psilocybin to treat anxiety and depression associated...
Journal of Psychopharmacology
May 30, 2022
Rebecca Smausz, Joanna C. Neill, John Gigg
60 citations
Psilocybin is a naturally occurring psychedelic compound with profound perception-, emotion- and cognition-altering properties and great potential for treating brain disorders. However, the neural mechanisms mediating its effects require in-depth investigation as there is still much to learn about how psychedelic drugs produce their profound and long-lasting effects. In this review, we outline...
Cureus
May 27, 2022
Robert Sotille, Herpreet Singh, Anne Weisman et al.
2 citations
Current medications have not been effective in reducing the prevalence of mental illness worldwide. The prevalence of illnesses such as treatment-resistant depression has increased despite the widespread use of a broad set of psychopharmaceuticals. Transcranial magnetic stimulation and ketamine therapy are making great strides in improving treatment-resistant depression outcomes but they have...
Psychiatric News
May 23, 2022
Richard Karel
A small study involving 24 participants found that psilocybin therapy was safe and effective up to one year following administration. More research using larger sample sizes is needed to further clarify efficacy and safety. A study on the safety and efficacy of psilocybin-assisted therapy in a therapeutic setting in 24 participants with major depressive disorder found that the hallucinogen...
Frontiers in Psychiatry
May 18, 2022
Joyce Huang, Michelle Pham, William J. Panenka et al.
19 citations
Background There are currently relatively few effective pharmacological treatments for obesity, and existing ones may be associated with limiting side-effects. In the search for novel anti-obesity agents, drugs that modify central serotonergic systems have historically proven to be effective in promoting weight loss. Psilocin, which is rapidly metabolized from psilocybin, is an agonist at...
Neurology International
May 18, 2022
Amber N. Edinoff, Juliana M. Fort, Christina Singh et al.
15 citations
With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate...
Current Psychiatry Research and Reviews
May 16, 2022
Andrew Hodge, Suporn Sukpraprut‐braaten, Robert Strayhan
4 citations
Background: The use of psychedelic compounds to treat psychiatric disorders has become a very significant topic of research over the past several years. Psilocybin has risen to prominence as one of the most studied among these psychedelic compounds. Multiple trials have already shown that it can be a safe and efficacious treatment for various medical conditions. This study intends to perform a...
Neuropharmacology
May 13, 2022
Cynthia E. Ortiz, Haley Maria Dourron, Noah W Sweat et al.
26 citations
Psilocybin-facilitated psychotherapy shows potential transdiagnostic efficacy for a range of mental health conditions. Though vulnerable populations bear disproportionate mental health burden, they have been largely neglected in the clinical psilocybin literature. However, if the field is to best respond to the diverse needs of individuals from vulnerable populations, care must be taken to...
May 10, 2022
Robin Carhart-Harris, Richard E. Daws, David Nutt
preprint
This document details an authors' response to a critique of their work entitled: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds.